Cubist Systematic Strategies, LLC 89bio, Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.13 - $13.77 $164,778 - $279,090	20,268 New	20,268 $235,000
Q1 2023 May 15, 2023	SELL	$10.48 - $16.94 $3.01 Million - $4.86 Million	-287,010 Reduced 98.62%	4,015 $61,000
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $1.37 Million - $3.16 Million	248,208 Added 579.69%	291,025 $3.7 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $52,774 - $122,325	17,475 Added 68.96%	42,817 $248,000
Q2 2022 Aug 15, 2022	BUY	$2.09 - $4.02 $13,396 - $25,768	6,410 Added 33.86%	25,342 $82,000
Q1 2022 May 16, 2022	BUY	$3.45 - $14.99 $65,315 - $283,790	18,932 New	18,932 $71,000
Q2 2021 Aug 16, 2021	SELL	$17.42 - $28.0 $236,215 - $379,680	-13,560 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$20.22 - $26.73 $274,183 - $362,458	13,560 New	13,560 $321,000
Q4 2020 Feb 16, 2021	SELL	$23.16 - $28.08 $145,444 - $176,342	-6,280 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $114,568 - $182,725	4,707 Added 299.24%	6,280 $161,000
Q2 2020 Aug 14, 2020	BUY	$19.93 - $31.2 $31,349 - $49,077	1,573 New	1,573 $31,000

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $387M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.